Zantac
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high levels of the carcinogen N-nitrosodimethylamine (NDMA). (Rodriguez et al v. Sanofi U.S. LLC et al, Case No. 19-cv-9527, S. D. NY.)
Class-Action Tracker
The Latest
PrettyLittleThing
The truth about sales advertised as sitewide can be ugly.
Consumers Continue to Report DealDash for Deceptive, Predatory Practices
Problems persist seven years after TINA.org complaint against penny auction site.
How the ‘Harvard of Trading’ Ruined Thousands of Young People’s Lives
Alice Kantor, Bloomberg
CATrends: Flea and Tick Products Marketed as Safe
Lawsuits allege products contain ingredients that are harmful to pets.
Lululemon’s ‘Be Planet’ Sustainability Campaign
Canadian law enforcement agency opens inquiry into apparel company’s green claims.